Cargando…
Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer
Background: Ovarian cancer (OC) represents the seventh most lethal female tumors worldwide. The combination of PARP inhibitor (PARPi) and angiogenic inhibitor has been shown to be effective as a first-line or second-line maintenance regimen to synergistically exert antitumor effects, which prompts u...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647199/ https://www.ncbi.nlm.nih.gov/pubmed/38021157 http://dx.doi.org/10.7150/jca.89082 |